Clinical trials: Esrd
Renal Impairment
A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003)
This purpose of this study is to evaluate the plasma pharmacokinetics (PK) of N-hydroxycytidine (NHC), the nucleoside metabolite of molnupiravir, after a single oral dose of 800 mg molnupiravir in participants with severe renal…
- Trial name
- NCT05386758
- Testing
- Molnupiravir
- Where
- 4 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Acute Kidney Injury
Guidance of Ultrasound in Intensive Care to Direct Euvolemia
The purpose of this study is to assess the effectiveness of routine ultrasound assessments of volume status and fluid responsiveness for goal-directed therapy (GDT)-based fluid resuscitation in reducing acute kidney injury (AKI)…
- Trial name
- GUIDE (NCT03938038)
- Testing
- Serial ultrasound assessments for GDT, Usual care
- Where
- United States
- Volunteers
- 415 people
- Sponsor
- The University of Texas Health Science Center, Houston
Acute Kidney Injury
Rapid Evaluation of Acute Kidney Injury With NGAL in Acutely Ill Patients in the ICU
This is a multi-center, prospective, observational study of patients that are admitted to the intensive care unit (ICU). This study does not include any treatment or intervention and it is considered Nonsignificant Risk.
- Trial name
- REAL-ICU (NCT01294228)
- Where
- 28 sites in United States, Canada
- Volunteers
- 1,001 people
- Sponsor
- Abbott RDx Cardiometabolic
Chronic Kidney Disease (CKD)
Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function
This was a randomized, double-blind, parallel group, placebo-controlled study, in two sequential parts that evaluated the renal safety, tolerability and pharmacokinetics of LHW090 in patients with moderately impaired renal…
- Trial name
- LHW090 (NCT02678000)
- Testing
- LHW090
- Where
- 12 sites in United States, Germany
- Volunteers
- 84 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
A Pragmatic Approach to CKD Patient Education
Over 350,000 adult Arkansans have chronic kidney disease (CKD) and 9 out of 10 (312,000) of these Arkansans are unaware of having it.
- Conditions
- Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 5, Patient Engagement
- Trial name
- PACED (NCT05138419)
- Testing
- CKD "What You Need To Know" Workbook System, CKD Action Plan, CKD Web-based Resource List
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Arkansas
Acute Kidney Injury
Epidemiology of Acute Kidney Injury in England - 1998 to 2013
The true population incidence of acute kidney injury (AKI), previously called acute renal failure, in England is not known. A better understanding of the epidemiology of AKI at a national level is essential to inform initiatives…
- Trial name
- NCT02216695
- Where
- United Kingdom
- Volunteers
- 64,882 people
- Sponsor
- University Hospitals of Derby and Burton NHS Foundation Trust
End-Stage Renal Disease
L-Carnitine in Peritoneal Dialysis
The development of glucose-sparing strategies able to provide an efficacious ultrafiltration profile represents one of the modern goals of peritoneal dialysis therapy.
- Trial name
- NCT00922701
- Testing
- L-carnitine
- Where
- Italy
- Volunteers
- 4 people
- Sponsor
- Iperboreal Pharma Srl
Kidney Disease, Chronic
Study of Heart and Renal Protection
The chief aim of SHARP was to determine whether lowering blood LDL cholesterol with simvastatin (20mg) plus ezetimibe (10mg) daily could safely reduce the risk of coronary heart disease, non-hemorrhagic stroke and the need for…
- Trial name
- SHARP (NCT00125593)
- Testing
- Simvastatin 20 mg, Ezetimibe 10mg
- Where
- United Kingdom
- Volunteers
- 9,438 people
- Sponsor
- University of Oxford
End-stage Renal Disease, Chronic Kidney Diseases
Increasing Live Donor Kidney Transplantation Through Video-based Education and Mobile Communication
The study is a- 2-arm randomized controlled trial among patients presenting for kidney transplant evaluation at a single transplant center to compare the effects of a patient-based self-learning and outreach intervention about…
- Trial name
- KidneyTIME (NCT05154773)
- Testing
- Kidney donation and transplant information made easy
- Where
- United States
- Volunteers
- 422 people
- Sponsor
- State University of New York at Buffalo
Chronic Kidney Disease, Inflammation
Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan.
The purpose of this research study is to compare the safety and effectiveness of 2 different doses of a study drug called ziltivekimab to placebo (an inactive substance) in reducing inflammation and improving some of the bad…
- Conditions
- Chronic Kidney Disease, Inflammation, Cardiovascular Risk
- Trial name
- RESCUE-2 (NCT04626505)
- Testing
- Ziltivekimab
- Where
- Japan
- Volunteers
- 36 people
- Sponsor
- Novo Nordisk A/S
Acute Kidney Injury, Pulmonary Embolism
Acute Kidney Injury in Patients Undergoing Contrast Exposure: VQ vs. CT
Both, CT scans and VQ scans, are used by doctors to look for pulmonary embolism. The most common reason to order a VQ scan is to avoid the IV dye.
- Conditions
- Acute Kidney Injury, Pulmonary Embolism, Contrast-induced Nephropathy
- Trial name
- VQ/CT (NCT03116139)
- Testing
- V/Q imaging, Computed tomography scan
- Where
- 5 sites in United States
- Volunteers
- 253 people
- Sponsor
- Indiana University
Secondary Hyperparathyroidism, Chronic Kidney Disease
Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT)
Secondary Hyperparathyroidism (SHPT) occurs in many patients with kidney disease and leads to bone disease. Active forms of vitamin D, calcitriol and paricalcitol, treat SHPT, but may have different effects on blood calcium.
- Trial name
- PACE (NCT00823303)
- Testing
- Paricalcitol, Calcitriol
- Where
- 4 sites in United States
- Volunteers
- 110 people
- Sponsor
- Washington University School of Medicine
Chronic Kidney Disease, End Stage Renal Disease
TARGTEPO Treatment for Anemia in Chronic Kidney Disease (CKD) Patients and End-Stage Renal Disease (ESRD)
The objectives of this study are to assess safety and to evaluate the biologic activity of TARGTEPO treatment.
- Trial name
- NCT02117427
- Testing
- MDGN201 TARGTEPO
- Where
- 5 sites in Israel
- Volunteers
- 11 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Acute Kidney Injury
Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery
This study evaluates RMC-035 compared to placebo for the prevention of acute kidney injury (AKI) in subjects who are at high risk for AKI following cardiac surgery.
- Trial name
- AKITA (NCT05126303)
- Testing
- RMC-035
- Where
- 29 sites in United States, Canada and 3 more
- Volunteers
- 177 people
- Sponsor
- Guard Therapeutics AB
End Stage Renal Disease
Effect of Adipokines in Hemodialysis Patients
This is a double blinded randomized clinical trial of pioglitazone vs. placebo in overweight or obese, diabetic and non-diabetic hemodialysis patients.
- Trial name
- NCT01301027
- Testing
- Pioglitazone
- Where
- 2 sites in United States
- Volunteers
- 95 people
- Sponsor
- University of Utah
Cardiac Failure, Renal Failure
Protocolized Diuretic Strategy in Cardiorenal Failure
This research study is a randomized clinical trial to evaluate if taking diuretics (medications that increase urine production and help with fluid removal from the body) in a standardized fashion (using a guideline for adjusting…
- Conditions
- Cardiac Failure, Renal Failure, Kidney Failure
- Trial name
- ProDiuS (NCT01921829)
- Testing
- Protocolized Diuretic Strategy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Kelly V. Liang, MD
End Stage Renal Disease
An Open Label Study to Allow Patients Continuous Use of the HemoCare™ Hemodialysis System
This study is designed to monitor and assess the safety of continued access to the HemoCare™ Hemodialysis System used during the review of the pre-market notifications for the devices in the HemoCare™ Hemodialysis System.
- Trial name
- NCT04198012
- Testing
- HemoCare™ Hemodialysis System
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- Deka Research and Development
End Stage Renal Disease
Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists
The purpose of this study is to evaluate the safety and efficacy of induction therapy with Thymoglobulin in comparison with IL2 receptor antagonists (daclizumab or basiliximab).
- Trial name
- NCT00859131
- Testing
- Rabbit Antithymocyte globulin, Daclizumab
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Medical University of South Carolina
Kidney Failure, Chronic
Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch
The purpose of this study is to determine whether the anti-T cell antibody, Thymoglobulin is a more effective induction medication than the anti-IL-2R inhibitor daclizumab, in kidney transplant recipients who have a positive…
- Trial name
- NCT00275509
- Testing
- Thymoglobulin, Daclizumab, Plasmapheresis
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Johns Hopkins University
Non-valvular Atrial Fibrillation
Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment
To assess the safety and pharmacokinetics of DU-176b administered to non-valvular atrial fibrillation patients with severe renal impairment, compared with DU-176b administered to non-valvular atrial fibrillation (NVAF) patients…
- Trial name
- NCT01857622
- Testing
- DU-176b 15mg, DU-176b 30mg, DU-176b 60mg
- Where
- Japan
- Volunteers
- 93 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.